Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.

By P. Ho, Thomas M. Maddox, Li Wang, S. Fihn, R. Jesse, E. Peterson, J. Rumsfeld. Journal of the American Medical Association (JAMA), 2009

1,076 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. (2009, background): “The commonly prescribed proton pump inhibitors omeprazole and esomeprazole, and some other medications commonly coprescribed with clopidogrel, such as cimetidine and fluoxitine, are potent inhibitors of CYP2C19, introducing the possibility that they may attenuate the antiplatelet activity of clopido”
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) (2009, methodology): “In a retrospective cohort study from the Veterans Affairs’ medical records and pharmacy database, concomitant clopidogrel and PPI therapy (with omeprazole, rabeprazole, lansoprazole, or pantoprazole) at any time point during follow-up of 8205 patients discharged for ACS was associated with an increa”